Pfizer 2014 Annual Report Download - page 48

Download and view the complete annual report

Please find page 48 of the 2014 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 75

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75

PFIZER ANNUAL REVIEW 2014 www.pzer.com/annual 48
ANNUAL REVIEW 2014
Our Science > Leading Medicines and Vaccines
OUR BEST SELLING MEDICINES AND VACCINES IN 2014
REVENUES FOR PRODUCTS
LEADING MEDICINES AND VACCINES
IMPROVING LIVES THROUGH
INNOVATIVE LIFE SCIENCE
Pfizer’s portfolio includes some of the most widely recognized and well-tested
treatments in the world.
LYRICA
(PREGABALIN)
$5,168 M
ENBREL
OUTSIDE THE U.S. AND CANADA
(ETANERCEPT)
$3,850 M
CELEBREX
(CELECOXIB)
$2,699 M
PREVNAR 13/
PREVENAR 13
(PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE)
$4,464 M